Health Canada Confirms BioPharma Services Inc. in Full Compliance Following Successful QI Inspection

TORONTO, April 22, 2025 — BioPharma Services Inc., a leading global Contract Research Organization (CRO), is pleased to announce the successful completion of a comprehensive Quality Inspection (QI) by Health Canada at its clinical research facility. The inspection was conducted in accordance with the Good Clinical Practices (GCP) Guideline – ICH E6 and Health Canada’s Food and Drug Regulations, Part C – Division 5.

Over the course of four days, Health Canada auditors conducted an in-depth review of BioPharma’s clinical operations, with particular focus on the performance and oversight of Principal Investigator, Dr. Janice Faulknor. The inspection concluded with BioPharma Services receiving an official designation of “In Compliance,” reaffirming the organization’s adherence to the highest regulatory standards for participant safety, data integrity, and clinical quality.

Dr. Faulknor commented that the expertise of BioPharma’s clinical and scientific teams, led by Vaideki Dharmaratnam, has made BPSI an industry leader, adding that she is honoured and grateful to be part of such an amazing, accomplished team.

Vaideki Dharmaratnam, Chief Compliance Officer at BioPharma Services, emphasized the organization’s commitment to quality, stating that the Principal Investigator’s exceptional expertise and unwavering dedication to participant safety and ethical conduct are at the heart of BioPharma’s clinical excellence.

This positive outcome underscores BioPharma’s dedication to maintaining world-class research standards and ensuring regulatory compliance. Recognition by Health Canada validates the organization’s ongoing efforts to conduct ethical, high-quality clinical trials that prioritize participant welfare and scientific rigor.

BioPharma Services remains committed to continuous quality improvement and to supporting global health initiatives through trustworthy and reliable research practices.